Magnesium Therapy: a Novel Platform for Neuroprotectant Sampling in Acute Stroke
Description
Brief Summary
This investigation will address the safety and feasibility of distal, intra-arterial sampling
through endovascular access, in acute stroke patients. Levels of Magnesium will be measured
in the region of infarct in patients who had been treated with intravenous Magnesium therapy
following an acute stroke. This study attempts to address whether the traditional intravenous
means of neuroprotectant administration achieves adequate concentration of the therapeutic
agent in the area of diseased tissue.
Phase
N/AInclusion and Exclusion Criteria
- Patient with acute cerebral ischemia due to ICA or MCA occlusion,
- Patient already enrolled in the NIH FAST-MAG clinical trial,
- Patient's clinical attending physician plans mechanical embolectomy procedure as part of routine clinical care.
- Age 40-95 inclusive (age criteria for FAST-MAG Trial).
- Technical inability to navigate microcatheter to target clot.
- Patient or surrogate unavailable for consent
Sites
-
California
- University of Southern California University and LA County Hospitals, Los Angeles, California, 90033
Powered by
SC CTSI